RNA
HEALTHCAREAtrium Therapeutics Inc
$13.09+0.18 (+1.39%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RNA Today?
No stock-specific AI insight has been generated for RNA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$11.95$16.77
$13.09
Fundamentals
Market Cap$203M
P/E Ratio—
EPS$-4.48
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.7%
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding15.5M
RNA News
20 articles- Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationYahoo Finance·Apr 23, 2026
- Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 21, 2026
- Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 BillionWall Street Journal·Mar 20, 2026
- Novartis Uses US Bond Issue To Expand RNA And Peptide PipelineYahoo Finance·Mar 19, 2026
- Novartis acquisition spin-off pioneers RNA therapeutics for the heartPharmavoice·Mar 19, 2026
- Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity DealYahoo Finance·Mar 17, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Mar 16, 2026
- Avidity (RNA) Moves Date for Shareholder Vote on Novartis MergerYahoo Finance·Feb 27, 2026
- European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation RisesYahoo Finance·Feb 27, 2026
- Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic CardiomyopathiesYahoo Finance·Feb 27, 2026
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategyYahoo Finance·Feb 27, 2026
- Atrium spins out of Avidity, aiming to target rare heart diseases with RNABiopharmadive·Feb 27, 2026
- Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceYahoo Finance·Feb 26, 2026
- Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersYahoo Finance·Feb 23, 2026
- The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1Yahoo Finance·Feb 18, 2026
- Avidity Biosciences Announces Expected Record Date for Spin-OffYahoo Finance·Feb 3, 2026
- Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?Yahoo Finance·Jan 22, 2026
- JPM26: Novartis strengthens neuroscience portfolio with bolt-on dealsPharmaceutical-technology·Jan 13, 2026
- Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price SurgeYahoo Finance·Dec 11, 2025
- Novartis Drops $1.7 Billion on AI Allergy BreakthroughYahoo Finance·Dec 9, 2025
All 20 articles loaded
Price Data
Open$12.94
Previous Close$12.91
Day High$13.30
Day Low$12.80
52 Week High$16.77
52 Week Low$11.95
52-Week Range
$11.95$16.77
$13.09
Fundamentals
Market Cap$203M
P/E Ratio—
EPS$-4.48
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.7%
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding15.5M
About Atrium Therapeutics Inc
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—